The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports Pub Date : 2025-01-01 DOI:10.1016/j.lrr.2025.100507

Mohamed I Sharif, Ahmad S. Alotaibi, Ruah Alyamany, Ali Alahmari, Hanan Alkhaldi, Ayman Saad, Mansour Alfayez

{"title":"The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia","authors":"Mohamed I Sharif, Ahmad S. Alotaibi, Ruah Alyamany, Ali Alahmari, Hanan Alkhaldi, Ayman Saad, Mansour Alfayez","doi":"10.1016/j.lrr.2025.100507","DOIUrl":null,"url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a heterogeneous disease with diverse molecular cytogenetic characteristics. Philadelphia-positive acute myeloid leukemia, a rare subtype of AML, is traditionally considered a high-risk, with the standard recommendation being an allogeneic hematopoietic cell transplant (HCT) in first remission. More recently, with better characterization and understanding of AML biology, novel therapies have been introduced. Drawing parallels from the advances seen in Philadelphia-positive acute lymphoblastic leukemia (ALL), the question arises whether potent tyrosine kinase inhibitors (TKI), such as ponatinib, in combination with AML-directed therapies, could be used in Philadelphia-positive AML, potentially eliminating the need for HCT in the first remission.</div><div>In this report, we review the literature on Philadelphia-positive AML, study a case where HCT was omitted, and explore potential signals that could support successful HCT omission.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100507"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048925000093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease with diverse molecular cytogenetic characteristics. Philadelphia-positive acute myeloid leukemia, a rare subtype of AML, is traditionally considered a high-risk, with the standard recommendation being an allogeneic hematopoietic cell transplant (HCT) in first remission. More recently, with better characterization and understanding of AML biology, novel therapies have been introduced. Drawing parallels from the advances seen in Philadelphia-positive acute lymphoblastic leukemia (ALL), the question arises whether potent tyrosine kinase inhibitors (TKI), such as ponatinib, in combination with AML-directed therapies, could be used in Philadelphia-positive AML, potentially eliminating the need for HCT in the first remission.

In this report, we review the literature on Philadelphia-positive AML, study a case where HCT was omitted, and explore potential signals that could support successful HCT omission.

查看原文本刊更多论文

未采取的道路：探索非移植选择在De Novo费城阳性急性髓性白血病

急性髓性白血病（AML）是一种具有多种分子细胞遗传学特征的异质性疾病。费城阳性急性髓性白血病是一种罕见的急性髓性白血病亚型，传统上被认为是高风险的，标准建议在首次缓解时进行同种异体造血细胞移植（HCT）。最近，随着对AML生物学的更好的描述和理解，新的治疗方法被引入。与费城阳性急性淋巴细胞白血病（ALL）的进展相似，问题出现了，是否有效的酪氨酸激酶抑制剂（TKI），如ponatinib，与AML靶向治疗联合，可以用于费城阳性AML，潜在地消除首次缓解时对HCT的需求。在本报告中，我们回顾了费城阳性AML的文献，研究了一个遗漏HCT的病例，并探讨了可能支持成功遗漏HCT的潜在信号。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊